PTAB affirms validity of three Medtronic patents in Axonics suit
The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.
Former FDA chief counsel joins Morrison & Foerster's DC office
Former Food and Drug Administration Chief Counsel Stacy Cline Amin has been hired as a partner at Morrison & Foerster’s life sciences and healthcare practice in Washington DC.
Zoetis sues rival over generic pet vomiting treatment
Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.
Lawmakers urge USPTO to curb IPR denials under Fintiv
Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.
Supernus hits Zydus with repeat suit over migraine drug
Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.
WHO plans to vaccinate Africa with Moderna COVID vaccine hit stumbling block
Just 12 African countries have hit WHO’s 10% vaccination target as supply chain issues worsen.
Intel backs Mylan's anti-Fintiv SCOTUS stance
Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.
Allergan closes the book on Fetzima generics suit
Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.
FDA urges USPTO to tackle rising drug costs
The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.
